Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]

Chen Wei Chiang; Yun Shih Lin; Fu Ling Chang; Tsai Yu Lin; Keng Chang Tsai; Wei Chun HuangFu; Yu Ching Lee

doi:10.1016/j.bbrc.2023.10.017

Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]

Chen Wei Chiang
, Yun Shih Lin
, Fu Ling Chang
, Tsai Yu Lin
, Keng Chang Tsai
, Wei Chun HuangFu
, Yu Ching Lee

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

摘要

The authors regret aPh.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan bDepartment of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan cPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan dNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan fTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan>. The authors would like to apologise for any inconvenience caused.

原文	英語
文章編號	149085
期刊	Biochemical and Biophysical Research Communications
卷	686
DOIs	https://doi.org/10.1016/j.bbrc.2023.10.017
出版狀態	已發佈 - 12月 17 2023

UN SDG

此研究成果有助於以下永續發展目標

SDG 3 良好的健康和福祉

ASJC Scopus subject areas

生物物理學
生物化學
分子生物學
細胞生物學

存取文件

10.1016/j.bbrc.2023.10.017

其它文件與鏈接

指紋

深入研究「Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]」主題。共同形成了獨特的指紋。

引用此

Chiang, C. W., Lin, Y. S., Chang, F. L., Lin, T. Y., Tsai, K. C., HuangFu, W. C., & Lee, Y. C. (2023). Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]. Biochemical and Biophysical Research Communications, 686, 文章 149085. https://doi.org/10.1016/j.bbrc.2023.10.017

Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]. / Chiang, Chen Wei; Lin, Yun Shih; Chang, Fu Ling 等.
於: Biochemical and Biophysical Research Communications, 卷 686, 149085, 17.12.2023.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

Chiang, CW, Lin, YS, Chang, FL, Lin, TY, Tsai, KC, HuangFu, WC & Lee, YC 2023, 'Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]', Biochemical and Biophysical Research Communications, 卷 686, 149085. https://doi.org/10.1016/j.bbrc.2023.10.017

Chiang CW, Lin YS, Chang FL, Lin TY, Tsai KC, HuangFu WC 等. Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]. Biochemical and Biophysical Research Communications. 2023 12月 17;686:149085. doi: 10.1016/j.bbrc.2023.10.017

@article{069a97c095bb4b6384c4decfe841bcd3,

title = "Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]",

abstract = "The authors regret aPh.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan bDepartment of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan cPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan dNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan fTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan>. The authors would like to apologise for any inconvenience caused.",

author = "Chiang, \{Chen Wei\} and Lin, \{Yun Shih\} and Chang, \{Fu Ling\} and Lin, \{Tsai Yu\} and Tsai, \{Keng Chang\} and HuangFu, \{Wei Chun\} and Lee, \{Yu Ching\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = dec,

day = "17",

doi = "10.1016/j.bbrc.2023.10.017",

language = "English",

volume = "686",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]

AU - Chiang, Chen Wei

AU - Lin, Yun Shih

AU - Chang, Fu Ling

AU - Lin, Tsai Yu

AU - Tsai, Keng Chang

AU - HuangFu, Wei Chun

AU - Lee, Yu Ching

PY - 2023/12/17

Y1 - 2023/12/17

N2 - The authors regret aPh.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan bDepartment of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan cPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan dNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan fTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan>. The authors would like to apologise for any inconvenience caused.

AB - The authors regret aPh.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan bDepartment of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan cPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan dNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan fTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan>. The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85173989559

UR - https://www.scopus.com/pages/publications/85173989559#tab=citedBy

U2 - 10.1016/j.bbrc.2023.10.017

DO - 10.1016/j.bbrc.2023.10.017

M3 - Comment/debate

C2 - 37839952

AN - SCOPUS:85173989559

SN - 0006-291X

VL - 686

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

M1 - 149085

ER -